Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06829173 · ClinicalTrials.gov registry record · Early Phase 1
Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
A Early Phase 1 study of High Grade Glioma, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT06829173: Recruiting Early Phase 1 study of High Grade Glioma, sponsored by NYU Langone Health.
NCT06829173 is a Early Phase 1 study of High Grade Glioma that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 39 participants, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06829173, a Early Phase 1 study of High Grade Glioma, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, dose-finding study of XRD-0394 in subjects with newly diagnosed and recurrent high grade gliomas receiving radiation therapy, with and without concurrent temozolomide based on O6-Methylguanine-DNA methyltransferase (MGMT) status for patients with newly diagnosed high grade gliomas.
Primary Outcome
Assessed among patients who receive at least one dose of the study drug and are evaluated for dose-limiting toxicities (DLTs).
Conditions Studied
Interventions
- PROCEDURE Surgical Resection
- RADIATION Radiation Therapy
- DRUG XRD-0394
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2025-11-05 |
| Est. Completion | 2031-05 |
| Phase | Early Phase 1 |
What NCT06829173 shows while recruiting
NCT06829173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (40% lower).
The record links to 1 condition, with High Grade Glioma appearing as the primary indexed condition, and to 3 interventions - of which Surgical Resection is the first listed.
NCT06829173 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06829173 about?
NCT06829173 is a clinical study titled "Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas". This is an open-label, dose-finding study of XRD-0394 in subjects with newly diagnosed and recurrent high grade gliomas receiving radiation therapy, with and without concurrent temozolomide based on O6-Methylguanine-DNA methyltransferase (MGMT) status for patients with newly diagnosed high grade gli...
What is the current status of trial NCT06829173?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2025-11-05. Estimated completion is 2031-05.
What conditions does trial NCT06829173 study?
This clinical trial studies the following conditions: High Grade Glioma.
What interventions are being tested in trial NCT06829173?
The interventions under investigation include: Surgical Resection (PROCEDURE), Radiation Therapy (RADIATION), XRD-0394 (DRUG).
Who is sponsoring clinical trial NCT06829173?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06829173 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06829173's enrollment target sits among peer trials
39 17th of 42 higher than 25 of 42 other High Grade Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other High Grade Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
RECRUITING · Early Phase 1
-
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
RECRUITING · Early Phase 1
-
Study of Sonodynamic Therapy in Participants with Recurrent High-Grade Glioma
RECRUITING · Early Phase 1
-
18F-Fluciclovine PET-MRI in High-grade Glioma
RECRUITING · Early Phase 1
-
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI